A short time ago, biopharmaceutical companies bemoaned the manufacturing bottlenecks that slowed drug development, delayed commercialization and increased costs. Now, between corporate mergers, technological improvements, and the rise of Asian biomanufacturing, the world may be facing excess bio-capacity. Moreover, geographic and development-stage mismatches between manufacturing supply and demand may prevent this growing glut from shrinking the costs of biologicals in world markets. This session brings together representatives from companies large and small around the world to illuminate the issues and explain how they are tackling the challenges of global biomanufacturing.

• Illuminate the fast-changing economics of biomanufacturing in a world of growing outsourced competition and corporate multinational consolidation
• Display the range of global models emerging in biomanufacturing and the impact these new approaches are having on world biomanufacturing capacity
• Provide practical insight for meeting the cost and technical challenges of developing and manufacturing biologicals in a dynamic global economy